Elizabeth Laughton is a litigator in the Los Angeles office of Munger, Tolles & Olson. She has represented major corporations in intellectual property and technology litigation. Among her areas of focus, Ms. Laughton litigates patent infringement disputes both in the district courts, as well as before the U.S. Court of Appeals for the Federal Circuit.
Ms. Laughton’s practice has spanned a wide range of technologies including pharmaceutical methods and products, steels, mobile and other software applications, semiconductor microfabrication, RFID technology, and business methods. She is registered to practice before the United States Patent & Trademark Office.
- Alien Technology in successfully briefing and arguing Federal Circuit appeal from inter partes reexamination on behalf of appellee, securing complete affirmance of Board’s decision finding all challenged claims invalid.
- Takeda Pharmaceuticals (and affiliates) in working to obtain a favorable settlement of patent infringement litigation against:
- three generic drug makers with respect to the gout medication Colcrys.
- multiple generic drug makers with respect to the gastroesophageal reflux disease (GERD) treatment Dexilant.
Prior to joining Munger Tolles, Ms. Laughton was an associate at a large law firm specializing in intellectual property. There, she gained significant experience in a variety of patent law matters, including patent prosecution, client counseling and opinion work, and patent litigation.
Ms. Laughton has also represented disabled veterans before the Court of Appeals for Veterans Claims and the U.S. Court of Appeals for the Federal Circuit in a pro bono capacity.
Following law school, Ms. Laughton served as a law clerk to Judge Timothy B. Dyk of the U.S. Court of Appeals for the Federal Circuit.
Ms. Laughton received her law degree from Duke University School of Law, where she was an editor on the Duke Law Journal and Duke Law & Technology Review, and was elected to the Order of the Coif.
Prior to law school, Ms. Laughton worked on a drug development program for new tuberculosis drugs. She received her undergraduate degree in biology with a minor in French Studies from Duke University.